Trials / Completed
CompletedNCT02338674
TDF and LdT in Immune-tolerant CHB Patients Awaiting Assisted Reproduction
Combination Therapy of Tenofovir and Telbivudine in Immune-tolerant Patients With Chronic Hepatitis B Awaiting Assisted Reproduction
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 121 (actual)
- Sponsor
- Fuzhou General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
Immune-tolerant patients with chronic hepatitis B (CHB) awaiting assisted reproduction (AR) are required to initiate antiviral therapy due to laboratory safety. Additionally, rapid virus elimination is suggested to faciliate timely performance of AR. However, no consensus is reached regarding the antiviral therapy in this group. This study aimed to explore the efficacy and safety of tenofovir (TDF) and telbivudine (LdT) in this population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tenofovir and telbivudine | tenofovir and telbivudine administered at least 48 weeks |
| DRUG | Tenofovir | tenofovir administered at least 48 weeks |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2016-10-01
- Completion
- 2017-10-01
- First posted
- 2015-01-14
- Last updated
- 2018-09-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02338674. Inclusion in this directory is not an endorsement.